Page last updated: 2024-12-11

motival

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Motival: combination of fluphenazine & nortriptyline [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	6455338
MeSH ID	M0090670

Synonyms (7)

Synonym
motipress
66555-51-9
motival
1-piperazineethanol, 4-(3-(2-(trifluoromethyl)-10h-phenothiazin-10-yl)propyl)-, dihydrochloride, mixt. with 3-(10,11-dihydro-5h-dibenzo(a,d)cyclohepten-5-ylidene)-n-methyl-1-propanamine hydrochloride
DTXSID10216731
n-methyl-3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenylidene)propan-1-amine;2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]piperazin-1-yl]ethanol;trihydrochloride
xqiumqdlobbwjm-uhfffaoysa-n

Research Excerpts

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (4)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	4 (100.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 76.13

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	76.13 (24.57)
Research Supply Index	2.30 (2.92)
Research Growth Index	4.45 (4.65)
Search Engine Demand Index	126.18 (26.88)
Search Engine Supply Index	2.00 (0.95)

This Compound (76.13)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	3 (50.00%)	5.53%
Reviews	1 (16.67%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	2 (33.33%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
fluphenazine [no description available]	5.18	4	3	N-alkylpiperazine; organofluorine compound; phenothiazines	anticoronaviral agent; dopaminergic antagonist; phenothiazine antipsychotic drug
nomifensine Nomifensine: An isoquinoline derivative that prevents dopamine reuptake into synaptosomes. The maleate was formerly used in the treatment of depression. It was withdrawn worldwide in 1986 due to the risk of acute hemolytic anemia with intravascular hemolysis resulting from its use. In some cases, renal failure also developed. (From Martindale, The Extra Pharmacopoeia, 30th ed, p266). nomifensine : An N-methylated tetrahydroisoquinoline carrying phenyl and amino substituents at positions C-4 and C-8, respectively.	3.35	1	1	isoquinolines	dopamine uptake inhibitor
nortriptyline Nortriptyline: A metabolite of AMITRIPTYLINE that is also used as an antidepressive agent. Nortriptyline is used in major depression, dysthymia, and atypical depressions.. nortriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(methylamino)propylidene group at position 5. It is an active metabolite of amitriptyline.	5.18	4	3	organic tricyclic compound; secondary amine	adrenergic uptake inhibitor; analgesic; antidepressant; antineoplastic agent; apoptosis inducer; drug metabolite

Condition	Relationship Strength	Studies	Trials
Bladder Diseases [description not available]	3.35	1	1
Symptom Cluster [description not available]	3.35	1	1
Urination Disorders Abnormalities in the process of URINE voiding, including bladder control, frequency of URINATION, as well as the volume and composition of URINE.	3.35	1	1
Syndrome A characteristic symptom complex.	3.35	1	1
Anxiety Neuroses [description not available]	3.35	1	1
Depression, Endogenous [description not available]	3.35	1	1
Anxiety Disorders Persistent and disabling ANXIETY.	3.35	1	1
Depressive Disorder An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent.	3.35	1	1
Colonic Diseases, Functional Chronic or recurrent colonic disorders without an identifiable structural or biochemical explanation. The widely recognized IRRITABLE BOWEL SYNDROME falls into this category.	3.75	2	1
Neuroses [description not available]	3.34	1	1
Neurotic Disorders Disorders in which the symptoms are distressing to the individual and recognized by him or her as being unacceptable. Social relationships may be greatly affected but usually remain within acceptable limits. The disturbance is relatively enduring or recurrent without treatment.	3.34	1	1

chemdatabank.com